What PharmApprove does

PharmApprove is a specialized consulting practice focused on high-stakes regulatory and scientific communications for pharmaceutical and biotechnology companies. Operating as the dedicated communications arm of SSI Strategy LLC (legal entity domiciled in New Jersey), the firm provides advisory and presentation support for pivotal regulatory interactions including FDA Advisory Committee meetings, EMA Oral Explanations, and Application Orientation meetings. Founded in 1998, the firm is headquartered in Morristown, New Jersey, and delivers services across North America and Europe.

The firm's service portfolio centers on four offerings: FDA Advisory Committee preparation, EMA Oral Explanation coaching, investor and partner presentation development, and strategic advisory board facilitation. Its methodology follows a structured workflow spanning in-depth gap analysis, narrative workshops, immersive mock rehearsals, final-hour rehearsals, and on-site execution support. The team is built around former FDA and EMA regulators, Key Opinion Leaders, patient advocates, and communications coaches, enabling the firm to bring an insider perspective to high-stakes client engagements.

PharmApprove generates revenue through project-based professional services engagements, with pricing conducted via quote-based proposals rather than publicly disclosed rates. The go-to-market motion is enterprise field sales, with direct engagement via phone, email, and website inquiry forms. The firm maintains a thought leadership presence through multiple podcast series including The Emerging Biotech Leader Podcast, Regulatory: The Emerging C-Suite Leader, and Build Talks, alongside published articles on regulatory strategy and FDA/EMA best practices.

Name

PharmApprove

Legal name

SSI Strategy LLC

Website

https://pharmapprove.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

PharmApprove is a specialized regulatory and scientific communications consultancy serving pharmaceutical and biotech sponsors. Operating under SSI Strategy LLC, the firm prepares clients for FDA Advisory Committee meetings, EMA Oral Explanations, and investor presentations using former regulators and KOLs.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Communications Consulting

NAICS

Other Management Consulting Services (541618)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

akta.pro secondary industry

KOL Engagement & Medical Education (Advisory Boards/CME Support) (HLAGALAM)

Keywords

• Regulatory communications consulting
• FDA advisory committee preparation
• EMA oral explanation coaching
• Biotech investor presentations
• Strategic advisory boards

Headquarters

HQ city

Lawrenceville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Regulatory Advisory Services: Professional consulting services for FDA Advisory Committee preparation, EMA Oral Explanations, and regulatory strategy. Services include in-depth gap analysis, narrative workshops, immersive mock sessions, and on-site execution support. Revenue is generated through project-based consulting engagements with pharmaceutical and biotech companies.
2. Strategic Advisory Boards & Workshops: Facilitation of tailored advisory boards and KOL workshops for trial designs, regulatory strategies, and commercial launches. Includes curation of expert panels and actionable insight generation.
3. Investor & Partner Presentation Services: Strategic communications support for investor pitches, board briefings, and partner presentations, including data-rich appendices for due diligence.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

PharmApprove provides strategic, regulatory, and scientific communications consulting to pharmaceutical and biotech sponsors preparing for high-stakes interactions with regulators, investors, and partners. Core offerings include FDA Advisory Committee preparation, EMA Oral Explanation coaching, investor and partner presentation development, and facilitation of strategic KOL advisory boards and workshops. Engagements are project-based and delivered end-to-end, from gap analysis and narrative workshops through mock rehearsals and on-site execution support.

Product overview

PharmApprove is SSI Strategy's high-stakes communications practice focused on regulatory and investor-facing presentation services. The company offers a unified suite of advisory services including FDA Advisory Committee Preparation, EMA Oral Explanation Preparation, Investor & Partner Presentations, and Strategic Advisory Boards & Workshops. These services work together to help pharmaceutical and biotech companies translate complex science into compelling narratives that drive regulatory approval decisions and secure investor backing.

Differentiator

Problem solved

Functional benefit

Products and services

• FDA Advisory Committee Preparation Preparation services for FDA Advisory Committee meetings, including narrative crafting, data presentation, and mock rehearsal sessions to help pharmaceutical and biotech sponsors achieve positive outcomes when facing FDA expert panels.
• EMA Oral Explanation Preparation Preparation for European Medicines Agency Oral Explanations, including 20-minute presentation delivery coaching and slide preparation within the two-day submission window, delivered by experts including former EMA reviewers and scientific advisors.
• Investor & Partner Presentations Strategic communications services for investor pitches and partner presentations, distilling scientific depth into persuasive investment theses with data-rich appendices for due diligence support across meetings, pitch contests, and board briefings.
• Strategic Advisory Boards & Workshops Facilitation of tailored external Key Opinion Leader panels, ex-regulators, and patient advocates to drive smarter trial designs, regulatory strategies, and commercial launches, including high-yield sessions that surface actionable insights and translate them into clear next steps.
• End-to-End High-Stakes Communications Comprehensive support spanning in-depth gap analysis and narrative workshops through immersive mock sessions, final-hour rehearsals, slide-recall hardware, and flawless on-site execution support for regulators, investors, and partners.

Quantifiable outcome

• FDA follows positive committee recommendations in 97% of cases and aligns with panel advice overall 88% of the time
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Emerging players

• Vantage Partners (Life Sciences): Advisory and negotiation consulting firm serving biotech on partnership strategy and stakeholder alignment — partially overlapping with PharmApprove's strategic advisory board and partner presentation services.
• Alacrita Consulting: Pharma and biotech consulting firm offering drug development, regulatory, and commercial strategy — an emerging player with partial overlap in regulatory strategy support for smaller biotech clients.

Broad incumbents

• Trinity Life Sciences: Life sciences strategy and insights consultancy covering clinical, regulatory, and commercial strategy — a broader incumbent with overlapping scientific communications and launch readiness work.
• Charles River Associates (Life Sciences Practice): Global consulting firm with a dedicated life sciences practice serving biopharma on strategy, regulatory economics, and commercial readiness — a broader incumbent with adjacent regulatory and value-communication services.
• Lumanity: Large life sciences commercialization consultancy offering broad medical communications, evidence, and access services — a broader incumbent with overlapping capabilities in regulatory narrative and scientific communications.

Direct peers

• Health Advances: Healthcare and life sciences consulting firm advising biopharma on strategy, value, and stakeholder communications — overlap with PharmApprove's KOL engagement, evidence translation, and biotech advisory work.
• Back Bay Life Science Advisors: Life sciences strategy and transaction advisory firm with dedicated scientific storytelling and investor presentation services — closely comparable to PharmApprove's investor/partner presentation practice.
• Defined Health (now part of Lumanity): Scientific and medical communications consultancy focused on biotech, helping clients craft narratives for investors, partners, and regulators — overlapping strongly with PharmApprove's investor presentation and strategic advisory offerings.
• NDA Group: Regulatory and drug development consultancy offering strategy, submissions, and scientific advice to pharma/biotech — directly comparable to PharmApprove's regulatory strategy and AdCom/Oral Explanation preparation, with overlap in principal experience (notably Laurie Smaldone Alsup's prior tenure).
• Scienta Communications: Specializes in FDA Advisory Committee preparation and regulatory communications for pharma/biotech sponsors — a direct competitor on the same core AdCom and oral explanation preparation services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmapprove

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmApprove